Osiris Therapeutics, Inc. (OSIR)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 7.80 / 19.30
Exchange NASDAQ
Div & Yield N.A. (N.A)
Relative Strength Alert For Osiris Therapeutics

Relative Strength Alert For Osiris Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of March 18th Options Trading For Osiris Therapeutics (OSIR)

First Week of March 18th Options Trading For Osiris Therapeutics (OSIR)

Investors in Osiris Therapeutics Inc saw new options become available this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OSIR options chain for the new March 18th contracts and identified the following call contract of particular interest.

Grafix Demonstrates Positive Clinical Outcomes In Chronic Complex Wounds With Exposed Tendon And Bone

Grafix Demonstrates Positive Clinical Outcomes In Chronic Complex Wounds With Exposed Tendon And Bone

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Confirms Dwayne Montgomery, As President And Chief Executive Officer, And The Election Of Thomas M. Brandt To The Board Of Directors

Osiris Confirms Dwayne Montgomery, As President And Chief Executive Officer, And The Election Of Thomas M. Brandt To The Board Of Directors

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is...

Short Interest In Osiris Therapeutics Makes 16% Move

Short Interest In Osiris Therapeutics Makes 16% Move

The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 593,706 share increase in total short interest for Osiris Therapeutics Inc , to 4,277,683, an increase of 16.12% since 01/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Osiris Therapeutics Announces Leadership Transition

Osiris Therapeutics Announces Leadership Transition

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Announces 100% Medicare Coverage For Grafix

Osiris Announces 100% Medicare Coverage For Grafix

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: HOLX, NOW, ZHNE Downgrades: ALJ, APAM, EFII, ESE, FNBC, HAIN, INVN, JOUT, LOGM, NSC, NYCB, OSIR, RES, ROK, SHOR, TATT, UTX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Osiris Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of January 22, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Osiris Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of January 22, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Osiris Therapeutics, Inc.

Osiris Responds To Statements About The Company Recently Posted To Several Websites

Osiris Responds To Statements About The Company Recently Posted To Several Websites

Osiris Therapeutics, Inc. (NASDAQ: OSIR) - Today, Osiris Therapeutics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Osiris Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of January 22, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Osiris Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of January 22, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Osiris Therapeutics, Inc.

January 22 Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Osiris Therapeutics, Inc.

January 22 Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Osiris Therapeutics, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors that a class action complaint has been filed on behalf of a class of Osiris Therapeutics, Inc.

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Remind Investors Of Class Action Involving Osiris Therapeutics, Inc. And A Lead Plaintiff Deadline Of January 22, 2016 - OSIR

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Remind Investors Of Class Action Involving Osiris Therapeutics, Inc. And A Lead Plaintiff Deadline Of January 22, 2016 - OSIR

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Osiris Therapeutics, Inc.

Osiris Therapeutics Becomes Oversold (OSIR)

Osiris Therapeutics Becomes Oversold (OSIR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

UPCOMING DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Osiris Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

UPCOMING DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Osiris Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of...

Buy These 5 Breakout Stocks Now for Big Gains

Buy These 5 Breakout Stocks Now for Big Gains

These stocks look ready to break out and trade higher from current levels.

Osiris Provides Update On Coverage For Grafix®

Osiris Provides Update On Coverage For Grafix®

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

SHAREHOLDER DEADLINE: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Osiris Therapeutics, Inc. And Reminds Investors With Losses To Contact The Firm

SHAREHOLDER DEADLINE: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Osiris Therapeutics, Inc. And Reminds Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Osiris Therapeutics, Inc.

SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Osiris Therapeutics, Inc. And Reminds Investors With Losses To Contact The Firm

SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Osiris Therapeutics, Inc. And Reminds Investors With Losses To Contact The Firm

Lundin Law PC announces a class action lawsuit has been filed against Osiris Therapeutics, Inc.

SECURITIES ALERT: Rosen Law Firm Reminds Osiris Therapeutics, Inc. Investors Of Important Deadline In Class Action Filed By Firm - OSIR

SECURITIES ALERT: Rosen Law Firm Reminds Osiris Therapeutics, Inc. Investors Of Important Deadline In Class Action Filed By Firm - OSIR

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Osiris Therapeutics, Inc.

Osiris Therapeutics To Present At The 27th Annual Piper Jaffray Healthcare Conference

Osiris Therapeutics To Present At The 27th Annual Piper Jaffray Healthcare Conference

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced...

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Osiris Therapeutics, Inc. And Urges Investors To Contact The Firm

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Osiris Therapeutics, Inc. And Urges Investors To Contact The Firm

Lundin Law PC announces it is investigating claims against Osiris Therapeutics, Inc.

Brower Piven, A Maryland-Based Securities Litigation Law Firm, Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Osiris Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

Brower Piven, A Maryland-Based Securities Litigation Law Firm, Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Osiris Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of...

Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Osiris Therapeutics, Inc. Investors

Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Osiris Therapeutics, Inc. Investors

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Osiris Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Osiris Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Osiris Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Osiris Therapeutics, Inc.

Kirby McInerney LLP Advises Osiris Therapeutics Inc. Investors Of Potential Claims

Kirby McInerney LLP Advises Osiris Therapeutics Inc. Investors Of Potential Claims

The law firm of Kirby McInerney LLP announced today that a class action lawsuit has been filed in the United States District Court for the District of Maryland against Osiris Therapeutics Inc.

Robbins Arroyo LLP Is Investigating The Officers And Directors Of Osiris Therapeutics, Inc. (OSIR) On Behalf Of Shareholders

Robbins Arroyo LLP Is Investigating The Officers And Directors Of Osiris Therapeutics, Inc. (OSIR) On Behalf Of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Osiris Therapeutics, Inc.

Osiris Therapeutics (OSIR) Weak On High Volume Today

Osiris Therapeutics (OSIR) Weak On High Volume Today

Trade-Ideas LLC identified Osiris Therapeutics (OSIR) as a weak on high relative volume candidate